AD-causing variants that affect PSEN1 transmembrane domains are associated with faster neurodegeneration and cognitive decline compared to those affecting cytoplasmic domains.

Stephanie A. Schultz, Ricardo Francisco Allegri, Aaron P. Schultz, Alison Goate, Allan I. Levey, Anne M. Fagan, Bernard J. Hanseeuw, Robert A. Koeppe, Brian A. Gordon, Carlos Cruchaga, Celeste M. Karch, Charles D. Chen, Chengjie Xiong, Clifford R. Jack, Colleen D. Fitzpatrick, Eric McDade, Helena C. Chui, Hiroshi Mori, Jae Hong Lee, James M. NobleJason J. Hassenstab, Johannes Levin, John C. Morris, Keith A. Johnson, Lei Liu, Martin R. Farlow, Mathias Jucker, Michelle E. Farrell, Neill R. Graff-Radford, Nelly Joseph-Mathurin, Nick C. Fox, Peter R. Schofield, Ralph N. Martins, Raquel Sanchez-Valle, Richard J. Perrin, Sarah Berman, Stephen P. Salloway, Zahra Shirzadi, Pedro Rosa-Neto, Tammie L.S. Benzinger, Randall J. Bateman, Reisa A. Sperling, Jasmeer P. Chhatwal

Research output: Contribution to journal › Comment/debate › peer-review

Fingerprint

Dive into the research topics of 'AD-causing variants that affect PSEN1 transmembrane domains are associated with faster neurodegeneration and cognitive decline compared to those affecting cytoplasmic domains.'. Together they form a unique fingerprint.

Medicine & Life Sciences

Social Sciences